<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01582165</url>
  </required_header>
  <id_info>
    <org_study_id>3tcAZ</org_study_id>
    <secondary_id>2011-002630-39</secondary_id>
    <nct_id>NCT01582165</nct_id>
  </id_info>
  <brief_title>Women With Chest Pain and no Significant Coronary Artery Stenosis; A Study on Microvascular Resistance</brief_title>
  <official_title>Microvascular Resistance in Women With Chest Pain and no or Minimal Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Female patients presenting with persistent chest pain despite no obstructive coronary artery
      disease have impaired prognosis. Stress tests are often positive or inconclusive. As much as
      20% of women with chest pain and minimal angiographic CAD have evidence of myocardial
      ischemia, suggesting impaired coronary microcirculation. The index of microvascular
      resistance (IMR) is a method for indirectly investigating microvascular function in the
      cardiac catheterization laboratory.

      66 female patients, age 30-70 years, with chest pain and &quot;normal&quot; or near normal coronary
      angiograms will be included. After coronary physiologic evaluation, patients will be
      randomized in a double blind study to rosuvastatin 20 mg/day or matching placebo tablets for
      altogether 6 months.

      The investigators hypothesize that:

        1. A substantial number of women with chest pain and normal or minimal pathology on
           angiograms have microvascular dysfunction defined by a raised IMR.

        2. Statins, based on its pleiotropic action will improve endothelial function and thereby
           IMR.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Temporal changes in microvascular perfusion indices (Index of Microvascular Function (IMR) and Coronary Flow Reserve (CFR)).</measure>
    <time_frame>6 months</time_frame>
    <description>During a left heart catheterization IMR and CFR are measured at baseline and at 6 months. Patients are randomized to rosuvastatin vs placebo. The objectives are to determine whether women with chest pain with no or minimal angiographic coronary artery disease, have a raised index of microvascular resistance and to determine whether high-dose statin treatment will modify microvascular perfusion indices in these patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angina pectoris classification (CCS).</measure>
    <time_frame>6 months</time_frame>
    <description>Women with chest pain are randomized to rosuvastatin vs placebo. Angina pectoris (CCS classification) will be compared in the two arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>Angina. IMR. Statin.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Angina. IMR. Placebo.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin 20 mg once daily vs placebo for 6 months</description>
    <arm_group_label>Angina. IMR. Statin.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo.</intervention_name>
    <description>Placebo once daily vs rosuvastatin for 6 months</description>
    <arm_group_label>Angina. IMR. Placebo.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female gender

          2. Age 30 - 70 years

          3. Chest pain suggestive of symptomatic coronary artery disease

          4. A coronary angiogram with no or minimal coronary artery disease

          5. Fractional flow reserve value over 0,80

        Exclusion Criteria:

          1. Male gender

          2. Age under 30 years or over 70

          3. Coronary artery stenosis ≥ 33 % in any epicardial vessel

          4. Fractional flow reserve value ≤ 0,80

          5. Pregnant or nursing women

          6. Women of childbearing potential not using contraception

          7. Short life expectancy

          8. Uncontrolled endocrinological disease

          9. Arterial hypertension

         10. Structural heart disease

         11. Significant mental disorder, including dementia

         12. Inability to comply with the protocol -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Aaberge, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital Rikshospitalet, Oslo, Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital, Dep of Cardiology, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0380</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Ole Geir Solberg</investigator_full_name>
    <investigator_title>Consultant, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chest Pain</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Analyses of the study will start within a few weeks or months. Publication planned in 2017</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

